Skip to main content

A unified drug discovery platform for protein misfolding diseases

Project description

Engineered bacteria in drug discovery efforts

Protein function relies on the proteins’ three-dimensional conformation and requires correct folding of the polypeptide chain. Protein misfolding leads to the accumulation of protein aggregates, which cause cellular toxicity and are a hallmark of diseases such as Alzheimer’s and Huntington’s. The EU-funded ProMiDis project is working on an innovative approach for the discovery of drugs that prevent protein misfolding. Researchers have engineered bacteria to produce drug-like molecules and identify those with an ability to inhibit protein misfolding and aggregation in mammalian cells. The proposed biotechnology platform is expected to pave the way towards the development of novel therapies against incurable diseases.

Host institution

BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING
Net EU contribution
€ 877 327,86
Address
Fleming Street 34
16672 Vari-athens
Greece

See on map

Region
Ανατολική Αττική Aττική Αττική
Activity type
Research Organisations
Other funding
€ 877 327,86

Beneficiaries (2)

BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING
Greece
Net EU contribution
€ 877 327,86
Address
Fleming Street 34
16672 Vari-athens

See on map

Region
Ανατολική Αττική Aττική Αττική
Activity type
Research Organisations
Other funding
€ 877 327,86
ETHNIKO IDRYMA EREVNON

Participation ended

Greece
Net EU contribution
€ 1 094 672,14
Address
Vas Konstantinou 48
11635 Athina
Region
Κεντρικός Τομέας Αθηνών Aττική Αττική
Activity type
Research Organisations
Other funding
€ 1 094 672,14